Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab).
Cetuximab
Chemotherapy
Metastases
Metastatic colorectal carcinoma
Psychological reactions
Quality of life
Skin rash
Journal
World journal of oncology
ISSN: 1920-454X
Titre abrégé: World J Oncol
Pays: Canada
ID NLM: 101564097
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
15
04
2021
accepted:
20
05
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
6
8
2021
Statut:
ppublish
Résumé
Metastatic colorectal cancer (mCRC) with wild type expression of RAS and RAF genes can be treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, such as cetuximab, in combination with chemotherapy. Skin toxicity represents the most serious and frequent side effect in these patients. Skin manifestations occur in approximately 80% of patients. In this study, we investigated the consequences on body image and quality of life (QoL) of patients with severe skin toxicity. One hundred patients were enrolled with mCRC. All patients signed informed consent and completed questionnaires to assess QoL and body discomfort. Toxicity was assessed on Common Terminology Criteria for Adverse Events (CTCAEs). The greatest impact on QoL was represented by difficulties in managing skin rash-related side effects. Data showed a significant impact in psychological sphere and social relationships. Skin side effects, particularly rash, influence QoL and social relationships, compromising therapeutic compliance.
Sections du résumé
BACKGROUND
BACKGROUND
Metastatic colorectal cancer (mCRC) with wild type expression of RAS and RAF genes can be treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, such as cetuximab, in combination with chemotherapy. Skin toxicity represents the most serious and frequent side effect in these patients. Skin manifestations occur in approximately 80% of patients. In this study, we investigated the consequences on body image and quality of life (QoL) of patients with severe skin toxicity.
METHODS
METHODS
One hundred patients were enrolled with mCRC. All patients signed informed consent and completed questionnaires to assess QoL and body discomfort. Toxicity was assessed on Common Terminology Criteria for Adverse Events (CTCAEs).
RESULTS
RESULTS
The greatest impact on QoL was represented by difficulties in managing skin rash-related side effects. Data showed a significant impact in psychological sphere and social relationships.
CONCLUSIONS
CONCLUSIONS
Skin side effects, particularly rash, influence QoL and social relationships, compromising therapeutic compliance.
Identifiants
pubmed: 34349854
doi: 10.14740/wjon1381
pmc: PMC8297050
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104-110Informations de copyright
Copyright 2021, De Luca et al.
Déclaration de conflit d'intérêts
None to declare.
Références
BMC Surg. 2013;13 Suppl 2:S15
pubmed: 24267735
Anticancer Res. 2017 Sep;37(9):5187-5192
pubmed: 28870953
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):34-6
pubmed: 18154217
Onco Targets Ther. 2018 May 24;11:3059-3063
pubmed: 29872317
CA Cancer J Clin. 1991 Mar-Apr;41(2):112-20
pubmed: 1900030
Cancer. 2008 Aug 15;113(4):847-53
pubmed: 18543329
Pflege. 2017 Jan;30(1):9-17
pubmed: 27901405
Qual Life Res. 2013 Dec;22(10):2685-91
pubmed: 23532341
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
pubmed: 15661684
J BUON. 2015 Mar-Apr;20(2):443-51
pubmed: 26011334
Support Care Cancer. 2010 Mar;18(3):329-34
pubmed: 19484487
J Clin Oncol. 2009 Apr 10;27(11):1822-8
pubmed: 19273701
Qual Life Res. 1993 Aug;2(4):287-95
pubmed: 8220363
Psychooncology. 2008 Apr;17(4):317-28
pubmed: 17721909
Oncology. 2007;72(3-4):152-9
pubmed: 18160805
J Clin Oncol. 2010 Feb 10;28(5):859-65
pubmed: 20065174
Target Oncol. 2009 Apr;4(2):107-19
pubmed: 19452131
Curr Oncol. 2009 Jan;16(1):16-26
pubmed: 19229368
Palliat Support Care. 2007 Dec;5(4):377-88
pubmed: 18044415
Medicine (Baltimore). 2020 Feb;99(6):e19029
pubmed: 32028414
Oncology. 2017;93(6):354-358
pubmed: 28873372
Cancer. 2004 Dec 15;101(12):2737-43
pubmed: 15536617
Aust N Z J Public Health. 2003;27(1):41-53
pubmed: 14705266
Oncology (Williston Park). 2009 Feb;23(2):186-94
pubmed: 19323301
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S40-6
pubmed: 17520580
N Engl J Med. 2004 Jul 22;351(4):337-45
pubmed: 15269313
Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):28-34
pubmed: 16616284
Z Gastroenterol. 2013 Aug;51(8):733-9
pubmed: 23955138
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1012-7
pubmed: 19880263
J Clin Oncol. 2010 Mar 10;28(8):1351-7
pubmed: 20142600